FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593461816> ?p ?o ?g. }

• W2593461816 endingPage "524" @default.
• W2593461816 startingPage "515" @default.
• W2593461816 abstract "Background Adjustment of mercaptopurine and methotrexate maintenance therapy of acute lymphoblastic leukaemia by leucocyte count is confounded by natural variations. Cytotoxicity is primarily mediated by DNA-incorporated thioguanine nucleotides (DNA-TGN). The aim of this study was to establish whether DNA-TGN concentrations in blood leucocytes during maintenance therapy are associated with relapse-free survival. Methods In this substudy of the NOPHO ALL2008 phase 3 trial done in 23 hospitals in seven European countries (Denmark, Estonia, Finland, Iceland, Lithuania, Norway, and Sweden), we analysed data from centralised and blinded analyses of 6-mercaptopurine and methotrexate metabolites in blood samples from patients with non-high-risk childhood acute lymphoblastic leukaemia. Eligible patients were aged 1·0–17·9 years; had been diagnosed with non-high-risk precursor B-cell or T-cell leukaemia; had been treated according to the Nordic Society of Pediatric Hematology and Oncology ALL2008 protocol; and had reached maintenance therapy in first remission. Maintenance therapy was (mercaptopurine 75 mg/m2 once per day and methotrexate 20 mg/m2 once per week, targeted to a leucocyte count of 1·5–3·0 × 109 cells per L). We measured DNA-TGN and erythrocyte concentrations of TGN nucleotides, methylated mercaptopurine metabolites, and methotrexate polyglutamates. The primary objective was the association of DNA-TGN concentrations and 6-mercaptopurine and methotrexate metabolites with relapse-free survival. The secondary endpoint was the assessment of DNA-TGN concentration and 6-mercaptopurine and methotrexate metabolites during maintenance therapy phase 2. Findings Between Nov 26, 2008 and June 14, 2016, 1509 patients from the NOPHO ALL2008 study were assessed for eligibility in the DNA-TGN substudy, of which 918 (89%) of 1026 eligible patients had at least one DNA-TGN measurement and were included in the analyses. Median follow-up was 4·6 years (IQR 3·1–6·1). Relapse-free survival was significantly associated with DNA-TGN concentration (adjusted hazard ratio 0·81 per 100 fmol/μg DNA increase, 95% CI 0·67–0·98; p=0·029). In patients with at least five blood samples, erythrocyte concentrations of TGN, methylated mercaptopurine metabolites, and methotrexate polyglutamates were associated with DNA-TGN concentration (all p<0·0001). Interpretation Our results suggest the need for intervention trials to identify clinically applicable strategies for individualised drug dosing to increase DNA-TGN concentration, and randomised studies to investigate whether such strategies improve cure rates compared with current dose adjustments based on white blood cell counts. Funding Danish Cancer Society, Childhood Cancer Foundation (Denmark), Childhood Cancer Foundation (Sweden), Nordic Cancer Union, Otto Christensen Foundation, University Hospital Rigshospitalet, and Novo Nordic Foundation." @default.
• W2593461816 created "2017-03-16" @default.
• W2593461816 creator A5001744506 @default.
• W2593461816 creator A5005257038 @default.
• W2593461816 creator A5017466426 @default.
• W2593461816 creator A5037827311 @default.
• W2593461816 creator A5047221635 @default.
• W2593461816 creator A5066050875 @default.
• W2593461816 creator A5074845542 @default.
• W2593461816 creator A5082379914 @default.
• W2593461816 creator A5083075511 @default.
• W2593461816 creator A5085002313 @default.
• W2593461816 creator A5086774156 @default.
• W2593461816 date "2017-04-01" @default.
• W2593461816 modified "2023-10-18" @default.
• W2593461816 title "DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial" @default.
• W2593461816 cites W104379152 @default.
• W2593461816 cites W170801347 @default.
• W2593461816 cites W1801876107 @default.
• W2593461816 cites W1911319577 @default.
• W2593461816 cites W1921422688 @default.
• W2593461816 cites W1970459379 @default.
• W2593461816 cites W1978042853 @default.
• W2593461816 cites W1992131964 @default.
• W2593461816 cites W1993379102 @default.
• W2593461816 cites W2024352108 @default.
• W2593461816 cites W2024884240 @default.
• W2593461816 cites W2035029649 @default.
• W2593461816 cites W2044141667 @default.
• W2593461816 cites W2048968984 @default.
• W2593461816 cites W2058471639 @default.
• W2593461816 cites W2061069132 @default.
• W2593461816 cites W2071818770 @default.
• W2593461816 cites W2076057372 @default.
• W2593461816 cites W2079689830 @default.
• W2593461816 cites W2084293321 @default.
• W2593461816 cites W2089190709 @default.
• W2593461816 cites W2089928288 @default.
• W2593461816 cites W2105410494 @default.
• W2593461816 cites W2115499099 @default.
• W2593461816 cites W2139540775 @default.
• W2593461816 cites W2147852317 @default.
• W2593461816 cites W2150604612 @default.
• W2593461816 cites W2157249349 @default.
• W2593461816 cites W2161927278 @default.
• W2593461816 cites W2170692626 @default.
• W2593461816 cites W2172173460 @default.
• W2593461816 cites W2307154186 @default.
• W2593461816 cites W2328999771 @default.
• W2593461816 cites W2336649003 @default.
• W2593461816 cites W2413038045 @default.
• W2593461816 cites W2480796907 @default.
• W2593461816 cites W2513725245 @default.
• W2593461816 cites W2577230177 @default.
• W2593461816 cites W4253242528 @default.
• W2593461816 doi "https://doi.org/10.1016/s1470-2045(17)30154-7" @default.
• W2593461816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28258828" @default.
• W2593461816 hasPublicationYear "2017" @default.
• W2593461816 type Work @default.
• W2593461816 sameAs 2593461816 @default.
• W2593461816 citedByCount "73" @default.
• W2593461816 countsByYear W25934618162017 @default.
• W2593461816 countsByYear W25934618162018 @default.
• W2593461816 countsByYear W25934618162019 @default.
• W2593461816 countsByYear W25934618162020 @default.
• W2593461816 countsByYear W25934618162021 @default.
• W2593461816 countsByYear W25934618162022 @default.
• W2593461816 countsByYear W25934618162023 @default.
• W2593461816 crossrefType "journal-article" @default.
• W2593461816 hasAuthorship W2593461816A5001744506 @default.
• W2593461816 hasAuthorship W2593461816A5005257038 @default.
• W2593461816 hasAuthorship W2593461816A5017466426 @default.
• W2593461816 hasAuthorship W2593461816A5037827311 @default.
• W2593461816 hasAuthorship W2593461816A5047221635 @default.
• W2593461816 hasAuthorship W2593461816A5066050875 @default.
• W2593461816 hasAuthorship W2593461816A5074845542 @default.
• W2593461816 hasAuthorship W2593461816A5082379914 @default.
• W2593461816 hasAuthorship W2593461816A5083075511 @default.
• W2593461816 hasAuthorship W2593461816A5085002313 @default.
• W2593461816 hasAuthorship W2593461816A5086774156 @default.
• W2593461816 hasConcept C126322002 @default.
• W2593461816 hasConcept C143998085 @default.
• W2593461816 hasConcept C194409129 @default.
• W2593461816 hasConcept C203014093 @default.
• W2593461816 hasConcept C2776694085 @default.
• W2593461816 hasConcept C2777173762 @default.
• W2593461816 hasConcept C2778283404 @default.
• W2593461816 hasConcept C2778461978 @default.
• W2593461816 hasConcept C2781059491 @default.
• W2593461816 hasConcept C2781107101 @default.
• W2593461816 hasConcept C2909962599 @default.
• W2593461816 hasConcept C535046627 @default.
• W2593461816 hasConcept C71924100 @default.
• W2593461816 hasConcept C98274493 @default.
• W2593461816 hasConceptScore W2593461816C126322002 @default.
• W2593461816 hasConceptScore W2593461816C143998085 @default.
• W2593461816 hasConceptScore W2593461816C194409129 @default.
• W2593461816 hasConceptScore W2593461816C203014093 @default.

• next